AGS2
MCID: ACR090
MIFTS: 32

Aicardi-Goutieres Syndrome 2 (AGS2)

Categories: Blood diseases, Bone diseases, Genetic diseases, Immune diseases, Neuronal diseases, Rare diseases, Skin diseases

Aliases & Classifications for Aicardi-Goutieres Syndrome 2

MalaCards integrated aliases for Aicardi-Goutieres Syndrome 2:

Name: Aicardi-Goutieres Syndrome 2 57 75 13 73
Ags2 57 53 75
Aicardi Goutieres Syndrome 2 29 6
Pseudo-Torch Syndrome 75 73
Rnaseh2b-Related Aicardi-Goutieres Syndrome 53
Aicardi-Goutieres Syndrome, Type 2 40
Aicardi-Goutieres Syndrome Type 2 53
Aicardi-Goutieres Syndrome 1 73
Cree Encephalitis 75

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive

Miscellaneous:
variable severity
onset in the first 2 years of life
progressive or slowly progressive


HPO:

32
aicardi-goutieres syndrome 2:
Onset and clinical course variable expressivity
Inheritance autosomal recessive inheritance


Classifications:



Summaries for Aicardi-Goutieres Syndrome 2

NIH Rare Diseases : 53 Aicardi-Goutieres syndrome is an inherited disease that mainly affects the brain, immune system, and the skin. Loss of white matter in the brain (leukodystrophy) and abnormal deposits of calcium (calcification) in the brain leads to an early-onset severe brain dysfunction (encephalopathy) that usually results in severe intellectual and physical disability.  Additional symptoms may include epilepsy, painful, itchy skin lesion (chilblains), vision problems, and joint and muscle stiffness (spasticity), involuntary muscle twisting and contractions (dystonia), and weak muscle tone (hypotonia) in the torso. Other signs and symptoms may include a very small head (microcephaly), presence of white blood cells and other sign of inflammation in the  cerebrospinal fluid, which is the fluid that surrounds the brain and spinal cord (central nervous system). Symptoms usually progress over several months before the disease course stabilizes.  There are several types of Aicardi-Goutieres syndrome, depending on the gene that causes the condition: TREX1, RNASEH2A, RNASEH2B, RNASEH2C, SAMHD1, ADAR and IFIH1, genes. Most cases are inherited in an autosomal recessive pattern, although rare autosomal dominant cases have been reported. Treatment is symptomatic and supportive. The prognosis depends mainly on the severity neurologic problems and in the age of onset of these problems.

MalaCards based summary : Aicardi-Goutieres Syndrome 2, also known as ags2, is related to aicardi-goutieres syndrome and pseudo-torch syndrome 1, and has symptoms including seizures, muscle spasticity and petechiae of skin. An important gene associated with Aicardi-Goutieres Syndrome 2 is RNASEH2B (Ribonuclease H2 Subunit B). Affiliated tissues include skin, brain and spinal cord, and related phenotypes are microcephaly and dystonia

UniProtKB/Swiss-Prot : 75 Aicardi-Goutieres syndrome 2: A form of Aicardi-Goutieres syndrome, a genetically heterogeneous disease characterized by cerebral atrophy, leukoencephalopathy, intracranial calcifications, chronic cerebrospinal fluid (CSF) lymphocytosis, increased CSF alpha-interferon, and negative serologic investigations for common prenatal infection. Clinical features as thrombocytopenia, hepatosplenomegaly and elevated hepatic transaminases along with intermittent fever may erroneously suggest an infective process. Severe neurological dysfunctions manifest in infancy as progressive microcephaly, spasticity, dystonic posturing and profound psychomotor retardation. Death often occurs in early childhood.

Description from OMIM: 610181

Related Diseases for Aicardi-Goutieres Syndrome 2

Graphical network of the top 20 diseases related to Aicardi-Goutieres Syndrome 2:



Diseases related to Aicardi-Goutieres Syndrome 2

Symptoms & Phenotypes for Aicardi-Goutieres Syndrome 2

Symptoms via clinical synopsis from OMIM:

57
Head And Neck Head:
microcephaly (in some patients)

Laboratory Abnormalities:
no evidence of common prenatal infections
increased interferon-alpha signal
lymphocytosis in the cerebrospinal fluid

Neurologic Central Nervous System:
dystonia (in some patients)
normal early development
neurologic dysfunction, progressive
spastic paraplegia (in some patients)
encephalopathy (in some patients)
more

Clinical features from OMIM:

610181

Human phenotypes related to Aicardi-Goutieres Syndrome 2:

32 (show all 8)
# Description HPO Frequency HPO Source Accession
1 microcephaly 32 occasional (7.5%) HP:0000252
2 dystonia 32 occasional (7.5%) HP:0001332
3 spastic paraplegia 32 occasional (7.5%) HP:0001258
4 encephalopathy 32 HP:0001298
5 cerebral atrophy 32 HP:0002059
6 lymphocytosis 32 HP:0100827
7 basal ganglia calcification 32 HP:0002135
8 chronic csf lymphocytosis 32 HP:0009704

UMLS symptoms related to Aicardi-Goutieres Syndrome 2:


seizures, muscle spasticity, petechiae of skin

Drugs & Therapeutics for Aicardi-Goutieres Syndrome 2

Interventional clinical trials:


# Name Status NCT ID Phase Drugs
1 Recognition and Treatment of Dysglycemia. AGS - Acute Glucose Service Recruiting NCT03306810 Not Applicable

Search NIH Clinical Center for Aicardi-Goutieres Syndrome 2

Genetic Tests for Aicardi-Goutieres Syndrome 2

Genetic tests related to Aicardi-Goutieres Syndrome 2:

# Genetic test Affiliating Genes
1 Aicardi Goutieres Syndrome 2 29 RNASEH2B

Anatomical Context for Aicardi-Goutieres Syndrome 2

MalaCards organs/tissues related to Aicardi-Goutieres Syndrome 2:

41
Skin, Brain, Spinal Cord, Bone

Publications for Aicardi-Goutieres Syndrome 2

Articles related to Aicardi-Goutieres Syndrome 2:

# Title Authors Year
1
Extensive intracranial calcification of pseudo-TORCH syndrome with features of Dandy-Walker malformation. ( 28761539 )
2017
2
Human USP18 deficiency underlies type 1 interferonopathy leading to severe pseudo-TORCH syndrome. ( 27325888 )
2016
3
Exposure-dependent Ag+ release from silver nanoparticles and its complexation in AgS2 sites in primary murine macrophages. ( 25824974 )
2015
4
Anaesthetic Management of a Patient with Pseudo-TORCH Syndrome. ( 25207129 )
2013
5
Two brothers with findings resembling congenital intrauterine infection-like syndrome (pseudo-TORCH syndrome). ( 12833411 )
2003
6
Pseudo-TORCH syndrome or Baraitser-Reardon syndrome: diagnostic criteria. ( 11226724 )
2001

Variations for Aicardi-Goutieres Syndrome 2

UniProtKB/Swiss-Prot genetic disease variations for Aicardi-Goutieres Syndrome 2:

75 (show all 14)
# Symbol AA change Variation ID SNP ID
1 RNASEH2B p.Leu60Arg VAR_027280 rs75325951
2 RNASEH2B p.His86Arg VAR_027281 rs77931005
3 RNASEH2B p.Lys162Thr VAR_027282 rs75971463
4 RNASEH2B p.Thr163Ile VAR_027283 rs79310911
5 RNASEH2B p.Ala177Thr VAR_027284 rs75184679
6 RNASEH2B p.Val185Gly VAR_027285 rs74555752
7 RNASEH2B p.Tyr219His VAR_027286 rs77391331
8 RNASEH2B p.Pro43His VAR_070611 rs79564863
9 RNASEH2B p.Trp73Leu VAR_070612 rs78071087
10 RNASEH2B p.Gly83Ser VAR_070613 rs76158094
11 RNASEH2B p.Leu138Phe VAR_070614 rs78705382
12 RNASEH2B p.Ser159Ile VAR_070615 rs76219783
13 RNASEH2B p.Val183Met VAR_070616 rs77377571
14 RNASEH2B p.Ser229Pro VAR_070617 rs768565639

ClinVar genetic disease variations for Aicardi-Goutieres Syndrome 2:

6 (show all 40)
# Gene Variation Type Significance SNP ID Assembly Location
1 RNASEH2B NM_024570.3(RNASEH2B): c.529G> A (p.Ala177Thr) single nucleotide variant Pathogenic/Likely pathogenic rs75184679 GRCh37 Chromosome 13, 51519581: 51519581
2 RNASEH2B NM_024570.3(RNASEH2B): c.529G> A (p.Ala177Thr) single nucleotide variant Pathogenic/Likely pathogenic rs75184679 GRCh38 Chromosome 13, 50945445: 50945445
3 RNASEH2B NM_001142279.2(RNASEH2B): c.554T> G (p.Val185Gly) single nucleotide variant Pathogenic rs74555752 GRCh37 Chromosome 13, 51519606: 51519606
4 RNASEH2B NM_001142279.2(RNASEH2B): c.554T> G (p.Val185Gly) single nucleotide variant Pathogenic rs74555752 GRCh38 Chromosome 13, 50945470: 50945470
5 RNASEH2B NM_001142279.2(RNASEH2B): c.356A> G (p.Asp119Gly) single nucleotide variant Likely pathogenic rs786205483 GRCh38 Chromosome 13, 50934919: 50934919
6 RNASEH2B NM_001142279.2(RNASEH2B): c.356A> G (p.Asp119Gly) single nucleotide variant Likely pathogenic rs786205483 GRCh37 Chromosome 13, 51509055: 51509055
7 RNASEH2B NM_001142279.2(RNASEH2B): c.509delA (p.Lys170Argfs) deletion Uncertain significance rs1085307091 GRCh38 Chromosome 13, 50943393: 50943393
8 RNASEH2B NM_001142279.2(RNASEH2B): c.509delA (p.Lys170Argfs) deletion Uncertain significance rs1085307091 GRCh37 Chromosome 13, 51517529: 51517529
9 RNASEH2B NM_024570.3(RNASEH2B): c.156G> A (p.Leu52=) single nucleotide variant Benign/Likely benign rs35416748 GRCh37 Chromosome 13, 51503630: 51503630
10 RNASEH2B NM_024570.3(RNASEH2B): c.156G> A (p.Leu52=) single nucleotide variant Benign/Likely benign rs35416748 GRCh38 Chromosome 13, 50929494: 50929494
11 RNASEH2B NM_024570.3(RNASEH2B): c.787A> G (p.Thr263Ala) single nucleotide variant Uncertain significance rs150363383 GRCh37 Chromosome 13, 51528086: 51528086
12 RNASEH2B NM_024570.3(RNASEH2B): c.787A> G (p.Thr263Ala) single nucleotide variant Uncertain significance rs150363383 GRCh38 Chromosome 13, 50953950: 50953950
13 RNASEH2B NM_024570.3(RNASEH2B): c.127C> T (p.Pro43Ser) single nucleotide variant Uncertain significance rs762281569 GRCh37 Chromosome 13, 51501605: 51501605
14 RNASEH2B NM_024570.3(RNASEH2B): c.127C> T (p.Pro43Ser) single nucleotide variant Uncertain significance rs762281569 GRCh38 Chromosome 13, 50927469: 50927469
15 RNASEH2B NM_024570.3(RNASEH2B): c.822+6T> C single nucleotide variant Benign/Likely benign rs76413207 GRCh37 Chromosome 13, 51528127: 51528127
16 RNASEH2B NM_024570.3(RNASEH2B): c.822+6T> C single nucleotide variant Benign/Likely benign rs76413207 GRCh38 Chromosome 13, 50953991: 50953991
17 RNASEH2B NM_024570.3(RNASEH2B): c.455A> G (p.Asn152Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs146451037 GRCh37 Chromosome 13, 51517475: 51517475
18 RNASEH2B NM_024570.3(RNASEH2B): c.455A> G (p.Asn152Ser) single nucleotide variant Conflicting interpretations of pathogenicity rs146451037 GRCh38 Chromosome 13, 50943339: 50943339
19 RNASEH2B NM_024570.3(RNASEH2B): c.859G> T (p.Ala287Ser) single nucleotide variant Benign/Likely benign rs144408326 GRCh37 Chromosome 13, 51530530: 51530530
20 RNASEH2B NM_024570.3(RNASEH2B): c.859G> T (p.Ala287Ser) single nucleotide variant Benign/Likely benign rs144408326 GRCh38 Chromosome 13, 50956394: 50956394
21 RNASEH2B NM_024570.3(RNASEH2B): c.412C> T (p.Leu138Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs78705382 GRCh37 Chromosome 13, 51509111: 51509111
22 RNASEH2B NM_024570.3(RNASEH2B): c.412C> T (p.Leu138Phe) single nucleotide variant Conflicting interpretations of pathogenicity rs78705382 GRCh38 Chromosome 13, 50934975: 50934975
23 RNASEH2B NM_024570.3(RNASEH2B): c.189A> G (p.Val63=) single nucleotide variant Benign rs35595258 GRCh37 Chromosome 13, 51503663: 51503663
24 RNASEH2B NM_024570.3(RNASEH2B): c.189A> G (p.Val63=) single nucleotide variant Benign rs35595258 GRCh38 Chromosome 13, 50929527: 50929527
25 RNASEH2B NM_024570.3(RNASEH2B): c.269C> T (p.Pro90Leu) single nucleotide variant Uncertain significance rs770203126 GRCh37 Chromosome 13, 51504843: 51504843
26 RNASEH2B NM_024570.3(RNASEH2B): c.269C> T (p.Pro90Leu) single nucleotide variant Uncertain significance rs770203126 GRCh38 Chromosome 13, 50930707: 50930707
27 RNASEH2B NM_024570.3(RNASEH2B): c.667G> T (p.Glu223Ter) single nucleotide variant Pathogenic GRCh38 Chromosome 13, 50948037: 50948037
28 RNASEH2B NM_024570.3(RNASEH2B): c.667G> T (p.Glu223Ter) single nucleotide variant Pathogenic GRCh37 Chromosome 13, 51522173: 51522173
29 RNASEH2B NM_024570.3(RNASEH2B): c.40C> T (p.Arg14Trp) single nucleotide variant Uncertain significance rs900876937 GRCh38 Chromosome 13, 50910116: 50910116
30 RNASEH2B NM_024570.3(RNASEH2B): c.40C> T (p.Arg14Trp) single nucleotide variant Uncertain significance rs900876937 GRCh37 Chromosome 13, 51484252: 51484252
31 RNASEH2B NM_024570.3(RNASEH2B): c.719C> G (p.Ser240Ter) single nucleotide variant Pathogenic rs372632599 GRCh38 Chromosome 13, 50949483: 50949483
32 RNASEH2B NM_024570.3(RNASEH2B): c.719C> G (p.Ser240Ter) single nucleotide variant Pathogenic rs372632599 GRCh37 Chromosome 13, 51523619: 51523619
33 RNASEH2B NM_024570.3(RNASEH2B): c.136+1delG deletion Pathogenic GRCh38 Chromosome 13, 50927479: 50927479
34 RNASEH2B NM_024570.3(RNASEH2B): c.136+1delG deletion Pathogenic GRCh37 Chromosome 13, 51501615: 51501615
35 RNASEH2B NM_024570.3(RNASEH2B): c.105_107delAAT (p.Met36del) deletion Uncertain significance GRCh38 Chromosome 13, 50927447: 50927449
36 RNASEH2B NM_024570.3(RNASEH2B): c.105_107delAAT (p.Met36del) deletion Uncertain significance GRCh37 Chromosome 13, 51501583: 51501585
37 RNASEH2B NM_024570.3(RNASEH2B): c.121delG (p.Val41Leufs) deletion Pathogenic GRCh37 Chromosome 13, 51501599: 51501599
38 RNASEH2B NM_024570.3(RNASEH2B): c.121delG (p.Val41Leufs) deletion Pathogenic GRCh38 Chromosome 13, 50927463: 50927463
39 RNASEH2B NM_024570.3(RNASEH2B): c.314A> C (p.Asp105Ala) single nucleotide variant Uncertain significance rs201078944 GRCh38 Chromosome 13, 50930752: 50930752
40 RNASEH2B NM_024570.3(RNASEH2B): c.314A> C (p.Asp105Ala) single nucleotide variant Uncertain significance rs201078944 GRCh37 Chromosome 13, 51504888: 51504888

Expression for Aicardi-Goutieres Syndrome 2

Search GEO for disease gene expression data for Aicardi-Goutieres Syndrome 2.

Pathways for Aicardi-Goutieres Syndrome 2

GO Terms for Aicardi-Goutieres Syndrome 2

Sources for Aicardi-Goutieres Syndrome 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....